Global sales of Bristol Myers Squibb’s and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% in 2026 due to ...
Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...
By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 revenue and profit above Wall Street ...
The Trump administration launched its new TrumpRx direct-to-consumer prescription drug listing site late Thursday, part of a ...
More than 8 million people in the U.S. take blood thinners, also called anticoagulants. Many are prescribed the drugs after ...
By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying ...
It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that ...
By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
The TrumpRx website is now live, which connects consumers directly with prescription drug manufacturers. The site lists 43 ...
All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...
Even so, overall prescription drug costs remain high. The Consumer Price Index for prescription drugs rose 2% between December 2024 and December 2025, and has fallen by less than 1% since Trump took ...
Pfizer has today reported fourth-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis and heart disease drug Vyndaqel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results